Work

A Phase I/II Trial of Ixazomib (Ix), Pomalidomide (POM), and Dexamethasone (DEX), in Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients: Responses in Double/Triple Refractory Myeloma and Poor Risk Cytogenetics

Year: 2016

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v128.22.3316.3316

Authors: Amrita Krishnan, Prashant Kapoor, Joycelynne Palmer, Ni-Chun Tsai, Shaji Kumar, Sagar Lonial, Myo Htut, Chatchada Karanes, Nitya Nathwani, Michael Rosenzweig, Firoozeh Sahebi, George Somlo, Lupe Duarte, Stephen J. Forman, James F Sanchez, Jesus G. Berdeja

Institutions: City Of Hope National Medical Center, City of Hope, Mayo Clinic, Emory University, Winship Cancer Institute, Sarah Cannon

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2750119425

FWCI: 2.374

Cites:

Cited by: 9

Related to: 10